EP Patent

EP1045840A1 — Hypolipidemic benzothiazepine compounds

Assigned to Glaxo Group Ltd · Expires 2000-10-25 · 26y expired

What this patent protects

The invention is concerned with novel hypolipidemic compounds of formula (I), wherein R1 is H or methyl, and salts, solvates or physiologically functional derivatives thereof, with processes and novel intermediates for their preparation, pharmaceutical compositions containing the…

USPTO Abstract

The invention is concerned with novel hypolipidemic compounds of formula (I), wherein R1 is H or methyl, and salts, solvates or physiologically functional derivatives thereof, with processes and novel intermediates for their preparation, pharmaceutical compositions containing them and with their use in medicine, particularly in the prophylaxis and treatment of hyperlipidermic conditions and associated diseases, such as atherosclerosis.

Drugs covered by this patent

Patent Metadata

Patent number
EP1045840A1
Jurisdiction
EP
Classification
—
Expires
2000-10-25
Drug substance claim
No
Drug product claim
No
Assignee
Glaxo Group Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.